Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Efficacy of consensus interferon in treatment of HbeAg-positive chronic hepatitis B: a multicentre, randomized controlled trial | Virology Journal BioMed Central Open Access Efficacy of consensus interferon in treatment of HbeAg-positive chronic hepatitis B a multicentre randomized controlled trial YongLi Zheng1 5 LianSan Zhao 1 TaiXiang Wu2 ShuHua Guo3 YaGang Chen4 and TaoYou Zhou1 Address infectious Disease Centre West China Hospital Sichuan University No. 37 Guo Xue Xiang Chengdu Sichuan Province PR China 2Department of Epidemiology West China Hospital of Sichuan University Chengdu Sichuan Province PR China 3Department of Infectious Diseases The Second Affiliated Hospital of ChongQing Medical University ChongQing PR China 4Center of Infectious Diseases The First Affiliated Hospital of Medical School of Zhejiang University Zhejiang Province PR China and 5Department of Infectious Diseases First People s Hospital of Yibin No. 65 Wen Xing Street Yibin Sichuan Province PR China Email YongLi Zheng - zhyl1973@ LianSan Zhao - zlsan@ TaiXiang Wu - txwutx@ ShuHua Guo - 188170370@ YaGang Chen - wendy7374@ TaoYou Zhou - marshelzty@ Corresponding author Published 9 July 2009 Received 30 May 2009 Virology Journal 2009 6 99 doi 1743-422X-6-99 Accepted 9 July 2009 This article is available from http content 6 1 99 2009 Zheng et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Consensus interferon CIFN is a newly developed type I interferon. Aims This multicentre controlled trial was conducted to determine the efficacy of CIFN and to compare it with alpha-lb-interferon IFN-alb in the treatment of patients with hepatitis B e antigen HBeAg -positive chronic hepatitis B. Methods 144 Patients were randomly assigned to receive 9 pg CIFN CIFN group or 50 pg INF-a1b .
